Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
[widgetkit id="2" name="CC Highlights"]
AACR & ASCO 2021 - Midyear Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Read More
AACR & ASCO 2021 - Midyear Review
Comparison of Aumolertinib and Gefitinib in First-Line Treatment of EGFR-Mutated NSCLC
Read More
AACR & ASCO 2021 - Midyear Review
Racial Disparities in Biomarker Testing and Clinical Trial Enrollment in NSCLC
Read More
AACR & ASCO 2021 - Midyear Review
Rucaparib in High Genomic Loss of Heterozygosity and/or BRCA1/2-Mutated NSCLC (Lung-MAP Sub-Study, S1900A)
Read More
AACR & ASCO 2021 - Midyear Review
Capmatinib in MET Exon 14–Mutated Advanced NSCLC (GEOMETRY Mono-1 Study)
Read More
AACR & ASCO 2021 - Midyear Review
Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)
Read More
AACR & ASCO 2021 - Midyear Review
Four-Year Update from CheckMate-227 Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Read More
AACR & ASCO 2021 - Midyear Review
Phase 1 Study of Telisotuzumab Vedotin in Patients with c-Met–Mutated Advanced NSCLC
Read More
AACR & ASCO 2021 - Midyear Review
Exciting New Data Presented on NSCLC at AACR 2021
David Spigel, MD
Read More
AACR & ASCO 2021 - Midyear Review
Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor
Read More
1
2
3
4
5
6
Page 3 of 22
Results 21 - 30 of 219